Identifying Modifiable Multi-Level Factors Associated With HPV Vaccine Uptake In Kenya And Malawi

Project Brief/Summary

The burden of cervical cancer falls disproportionately on women in low- and middle-income countries. For primary cervical cancer prevention, Kenya and Malawi introduced the Human Papillomavirus (HPV) Vaccine in 2019, but uptake is low, and the underlying reasons are understudied. To design effective programs and interventions, this project aims to understand the drivers and challenges related to HPV vaccine uptake.

The African Population and Health Research Center (APHRC) is leading Aim 1 and the knowledge translation aspects of this project.

In Aim 1, APHRC is implementing a qualitative design to understand the policy, systems, and community-level context for HPV vaccine delivery by collecting primary and secondary data (key informant interviews with stakeholders and a policy review of the policy and program implementation documents. 

This policy study examines the experiences with the HPV vaccine in Kenya and Malawi, aligning with the sexual reproductive health signature issue. These countries were selected because they have a high burden of cervical cancer and low HPV vaccination uptake.

Team

• Corrina Moucheraud – Principal Investigator (PI), New York University
• Lynette Kamau – Co-principal investigator (C-PI), APHRC
• Ramatou Ouedraogo – Co-principal investigator (C-PI), APHRC
• Erick Muge, APHRC
• Cynthia Kairu, APHRC
• Mauline Onyancha, APHRC
• Beryl Machoka, APHRC

Duration (start to end)

June 1, 2024 – May 31, 2029

Partners

New York University
Innovation for Poverty Action (IPA)
Kenya Medical Research Institute (KEMRI)

Funder

US National Institutes of Health/National Cancer Institute